Union Korea Pharm Co., Ltd. (KOSDAQ:080720)
South Korea · Delayed Price · Currency is KRW 2,725.00
-310.00 (-10.21%)
At close: Oct 11, 2024
Union Korea Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 33,831 | 51,280 | 63,169 | 61,293 | 48,304 | 50,379 |
Other Revenue | -0 | - | -0 | - | - | - |
| 33,831 | 51,280 | 63,169 | 61,293 | 48,304 | 50,379 | |
Revenue Growth (YoY) | -47.22% | -18.82% | 3.06% | 26.89% | -4.12% | -1.73% |
Cost of Revenue | 32,546 | 37,156 | 42,388 | 37,377 | 33,154 | 31,113 |
Gross Profit | 1,285 | 14,124 | 20,781 | 23,917 | 15,150 | 19,267 |
Selling, General & Admin | 20,429 | 27,587 | 24,675 | 22,147 | 23,987 | 24,077 |
Research & Development | 781.42 | 1,027 | 833.33 | 922.15 | 2,451 | 988.78 |
Amortization of Goodwill & Intangibles | 115.86 | 301.46 | 311.24 | 350.72 | 368.82 | 366.77 |
Other Operating Expenses | 266.56 | 264.02 | 244.29 | 294.22 | 196.45 | 190.14 |
Operating Expenses | 29,133 | 32,734 | 35,463 | 22,646 | 25,764 | 30,098 |
Operating Income | -27,848 | -18,610 | -14,682 | 1,271 | -10,615 | -10,832 |
Interest Expense | -2,668 | -3,920 | -4,112 | -2,843 | -2,229 | -667.41 |
Interest & Investment Income | 29.56 | 97.74 | 105.43 | 47.61 | 46.64 | 40.06 |
Earnings From Equity Investments | -33.18 | -23.89 | -19.46 | -5.47 | -9.49 | - |
Currency Exchange Gain (Loss) | 22.08 | 89.97 | 9.98 | -55.14 | 96.43 | -108.66 |
Other Non Operating Income (Expenses) | 3,119 | 7,264 | 1,695 | 2,528 | -1,628 | -210.37 |
EBT Excluding Unusual Items | -27,379 | -15,102 | -17,004 | 943.54 | -14,338 | -11,778 |
Gain (Loss) on Sale of Assets | 35.24 | 0.67 | 129.04 | - | 7.54 | -306.31 |
Asset Writedown | - | - | - | - | -146.73 | - |
Other Unusual Items | -1,127 | -3,826 | 2,471 | - | - | - |
Pretax Income | -28,470 | -18,928 | -14,404 | 943.54 | -14,477 | -12,084 |
Income Tax Expense | 1,947 | 1,944 | 3,753 | 1,876 | -3,367 | -2,762 |
Net Income | -30,417 | -20,872 | -18,156 | -932.02 | -11,109 | -9,322 |
Net Income to Common | -30,417 | -20,872 | -18,156 | -932.02 | -11,109 | -9,322 |
Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 8 | 7 |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 8 | 7 |
Shares Change (YoY) | 5.94% | 0.10% | -2.14% | -5.05% | 16.95% | 12.55% |
EPS (Basic) | -4090.26 | -2887.58 | -2514.45 | -126.31 | -1429.59 | -1430.75 |
EPS (Diluted) | -4090.67 | -2888.00 | -2514.45 | -126.31 | -1430.00 | -1430.75 |
Free Cash Flow | 178.83 | -534.23 | -901.15 | -8,429 | -5,254 | -10,039 |
Free Cash Flow Per Share | 24.05 | -73.91 | -124.80 | -1142.33 | -676.09 | -1510.90 |
Gross Margin | 3.80% | 27.54% | 32.90% | 39.02% | 31.36% | 38.24% |
Operating Margin | -82.31% | -36.29% | -23.24% | 2.07% | -21.98% | -21.50% |
Profit Margin | -89.91% | -40.70% | -28.74% | -1.52% | -23.00% | -18.50% |
Free Cash Flow Margin | 0.53% | -1.04% | -1.43% | -13.75% | -10.88% | -19.93% |
EBITDA | -25,783 | -15,733 | -10,792 | 5,266 | -6,389 | -7,084 |
EBITDA Margin | -76.21% | -30.68% | -17.08% | 8.59% | -13.23% | -14.06% |
D&A For EBITDA | 2,065 | 2,877 | 3,890 | 3,994 | 4,226 | 3,747 |
EBIT | -27,848 | -18,610 | -14,682 | 1,271 | -10,615 | -10,832 |
EBIT Margin | -82.31% | -36.29% | -23.24% | 2.07% | -21.98% | -21.50% |
Effective Tax Rate | - | - | - | 198.78% | - | - |
Advertising Expenses | - | 302.81 | 1,984 | 865.84 | 1,090 | 1,618 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.